Scribd Logo
Upload

Welcome to Scribd!

  • Vein To Vein Diagram

    Uploaded by

    Prashant Tripathi
    6 views2 pages
    This document describes the process for manufacturing and delivering NexCAR19, a CAR T-cell therapy. The process involves: 1. Extracting a patient's white blood cells through leukapheresis at the hospital. 2. Shipping the extracted cells to the manufacturing site for selection, activation, and genetic modification of T-cells to target B-cell cancer. 3. Testing and cryopreserving the manufactured product before shipping back to the hospital within 9-19 days for intravenous infusion into the patient.

    Original Description:

    Car t cells therapy for cancer treatment

    Original Title

    Vein to Vein diagram

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document describes the process for manufacturing and delivering NexCAR19, a CAR T-cell therapy. The process involves: 1. Extracting a patient's white blood cells through leukapheresis at the hospital. 2. Shipping the extracted cells to the manufacturing site for selection, activation, and genetic modification of T-cells to target B-cell cancer. 3. Testing and cryopreserving the manufactured product before shipping back to the hospital within 9-19 days for intravenous infusion into the patient.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    6 views2 pages

    Vein To Vein Diagram

    Uploaded by

    Prashant Tripathi
    This document describes the process for manufacturing and delivering NexCAR19, a CAR T-cell therapy. The process involves: 1. Extracting a patient's white blood cells through leukapheresis at the hospital. 2. Shipping the extracted cells to the manufacturing site for selection, activation, and genetic modification of T-cells to target B-cell cancer. 3. Testing and cryopreserving the manufactured product before shipping back to the hospital within 9-19 days for intravenous infusion into the patient.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    TM

    NexCAR19
    Actalycabtagene autoleucel
    From Vein-to-Vein

    Hospital Manufacturing Site


    Patient consent &
    enrollment

    Day 0 Shipping Day 1 - Day 9


    Leukapheresis (The Leukopak is shipped Manufacturing
    (White Blood Cells to ImmunoACT’s (ImmunoACT’s scientists select and activate the T-cells, then modify them using a safe
    are extracted by a manufacturing facility lentiviral vector. This makes the T-cells express special connectors, called Chimeric Antigen
    machine at the under refrigerated Receptors (CARs) that target your B-cell cancer. The cells are then cultured and expanded
    Hospital, in a conditions) until they reach a target dose)
    Leukopak)

    Product Quality Formulation and


    Assurance Cryopreservation

    Infusion Day 9-19


    (The Product is administered via Shipping
    intravenous infusion. Prior to this, (The Product is shipped in (The Product is cryopreserved, and
    the patient is given a conditioning an Infusion bag under undergoes extensive testing to ensure its
    chemotherapy to ready their body cryopreserved conditions to Identity, Purity, Safety, & Potency)
    for the treatment) the hospital)

    You might also like